at Benzinga.com (Dec 30, 2014)
William Blair is cutting its price target to $4 from $5 on Dendreon (DNDN -5.2%) after Friday's Q3 showed Provenge sales missing expectations. The firm says sales of the drug are likely to remain challenged over the near term, and keeps an Underperform rating on the stock. CFO Doug Schiffman acknowledged in the company's earning call on Friday that the drug has faced some marketing challenges over the past quarter due in part to the departure of some key sales personnel in many of its key markets. (Transcript)
How did this change your view of ?
More Bullish More Bearish It Didn't
This impact ()
Thanks for sharing your thoughts.
Submit & View Results
From other sites
at Zacks.com (Nov 18, 2014)
at Zacks.com (Nov 11, 2014)
at CNBC.com (Nov 10, 2014)
at Zacks.com (Nov 10, 2014)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs